et al. ARX788, a site-specific anti-HER2 antibody–drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers. Mol. Cancer Ther. 19, 1833–1843 (2020). CAS PubMed Google Scholar Yamazaki, C. M. et al. Antibody–drug conjugates...
a novel topoisomerase I inhibitor payload. It is approved in US and Japan for patients with advanced or metastatic HER2-positive BC after at least two prior anti-HER2-based regimens and is under accelerated assessment in Europe. In 2020, the Food and Drug Administration...
Antibody‒drug conjugate using ionized cys-linker-MMAE as the potent payload shows optimal therapeutic safety Cancers (Basel), 12 (2020), p. 744 View PDFView articleGoogle Scholar 60 X. Li, J.T. Patterson, M. Sarkar, L. Pedzisa, T. Kodadek, W.R. Roush, et al. Site-specific dual...
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates 2023, Translational Lung Cancer Research Antibody-drug Conjugate Targets, Drugs, and Linkers 2022, Current Cancer Drug Targets ...
The antibody drug conjugate MORAb2, consisting of farletuzumab paired with a cathepsin Bヽleavable linker and eribulin, targets folate receptor alpha (FRA), which is frequently overexpressed on various tumor types. MORAb2 was highly cytotoxic to FRA﹑ositive cells in vitro, with limited off‐...
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to a
Trop-2 protein as a therapeutic target: a focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers. Bosn J Basic Med Sci. 2022;22:14–21. CAS PubMed Google Scholar Syed YY. Sacituzumab Govitecan: first approval. Drugs. 2020;80:1019–25. Article CAS Pub...
抗体偶联药物(Antibody-Drug Conjugates,ADCs)将靶向抗体疗法与强效细胞毒性药物相结合,已成为肿瘤学领域的一项关键创新,其应用从血液肿瘤已经发展到实体瘤。以泌尿系统肿瘤为例,在尿路上皮癌中,世界范围内已经有3款ADCs获批上市。结合以下内容,我们一起对ADCs在泌尿系统恶性肿瘤中的临床研究进展进行了总结和展望。
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. JAMA Oncol. 2021 Dec 1;7(12):1873-1881. doi:10.1001/jamaoncol.2021.3595. Zhang L, Ma Y, Zhao Y, et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in ...
A comprehensive review of key factors affecting the efficacy of antibody drug conjugate AnupamaSamantasinghar, ...Kyung HyunChoi, inBiomedicine & Pharmacotherapy, 2023 1Introduction Antibody Drug Conjugate(ADC) is an emerging class of potent biological drugs that combine a highly potent cytotoxic ...